These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 39159054

  • 1. The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy.
    Duinkerken CW, Chiodo S, Hueniken K, Hauptmann M, Jóźwiak K, Cheng D, Hope A, Liu G, Zuur CL.
    Cancer Med; 2024 Aug; 13(16):e7465. PubMed ID: 39159054
    [Abstract] [Full Text] [Related]

  • 2. Validation of Hearing Loss Prediction Tool for Cisplatin Chemotherapy and Radiation in Head and Neck Cancer Treatment.
    Deutsch BC, Collopy C, Kallogjeri D, Piccirillo JF.
    JAMA Otolaryngol Head Neck Surg; 2021 Feb 01; 147(2):182-189. PubMed ID: 33300954
    [Abstract] [Full Text] [Related]

  • 3. Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer.
    Schuette A, Lander DP, Kallogjeri D, Collopy C, Goddu S, Wildes TM, Daly M, Piccirillo JF.
    JAMA Otolaryngol Head Neck Surg; 2020 Feb 01; 146(2):106-112. PubMed ID: 31750863
    [Abstract] [Full Text] [Related]

  • 4. Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy.
    Theunissen EA, Zuur CL, Józwiak K, Lopez-Yurda M, Hauptmann M, Rasch CR, van der Baan S, de Boer JP, Dreschler WA, Balm AJ.
    JAMA Otolaryngol Head Neck Surg; 2015 Sep 01; 141(9):810-5. PubMed ID: 26291150
    [Abstract] [Full Text] [Related]

  • 5. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.
    Essers PBM, van der Heijden M, Vossen D, de Roest RH, Leemans CR, Brakenhoff RH, van den Brekel MWM, Bartelink H, Verheij M, Vens C.
    Int J Cancer; 2020 Sep 15; 147(6):1732-1739. PubMed ID: 32167160
    [Abstract] [Full Text] [Related]

  • 6. Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients.
    Schmitt NC, Page BR.
    Int J Audiol; 2018 Sep 15; 57(sup4):S49-S54. PubMed ID: 28728452
    [Abstract] [Full Text] [Related]

  • 7. Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.
    Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Limaye S, Damjanov N, Di Stefano J, Ciunci C, Genden EM, Wisnivesky JP, Ferrandino R, Mamtani R, Langer CJ, Cohen RB, Sigel K.
    J Natl Cancer Inst; 2019 May 01; 111(5):490-497. PubMed ID: 30239887
    [Abstract] [Full Text] [Related]

  • 8. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
    van der Vorst MJDL, Neefjes ECW, Toffoli EC, Oosterling-Jansen JEW, Vergeer MR, Leemans CR, Kooistra MP, Voortman J, Verheul HMW.
    BMC Cancer; 2019 Nov 08; 19(1):1066. PubMed ID: 31703649
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment.
    Duran G, Aguín S, Cruz R, Barros F, Giráldez JM, Bernárdez B, López-López R, Carracedo Á, Lamas MJ.
    Head Neck; 2019 Aug 08; 41(8):2704-2715. PubMed ID: 30973677
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Schornagel JH, Dreschler WA, Rasch CR, Balm AJ.
    J Clin Oncol; 2007 Aug 20; 25(24):3759-65. PubMed ID: 17704425
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.